## Conclusions

Different FcγRs have different affinities for the different subtypes of IgG molecules. Since the present study only used antibodies of one subtype, even though their variable regions were targeted against two very different proteins (one a cell-surface receptor and one an intracellular enzyme), the affinities of the FcγRIIIa for both antibodies were comparable. These assays demonstrate the ease and utility of utilizing LANCE *Ultra*, a homogeneous assay format, for determining binding profiles of therapeutic mAbs to FcγRs. On account of its no-wash format it allows for determination of low-affinity interactions, e.g. when engineering a mAb to have no ADCC activation one can pick up lower levels of affinity for an FcγR than with other assay technologies.

**PerkinElmer, Inc.**
940 Winter Street
Waltham, MA 02451 USA
P: (800) 762-4000 or
(+1) 203-925-4602
**www.perkinelmer.com**

PerkinElmer®

**For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs**

Copyright ©2017, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.

013512_01 PKI

DRAFT